In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Regulatory matters are expected to take up a sizable chunk of time on mutual fund boards' 2021 agendas. The new rule on fair valuation practices is ...
The Securities and Exchange Commission on Thursday adopted a new rule on fund valuation practices, the first comprehensive update in 50 years. Rule 2a-5 will permit ...
It's a good thing Carolyn McPhillips had the experience she did when she took the helm at Mutual Fund Directors Forum last June because she had ...
The Morningstar Funds board has called on the Securities and Exchange Commission to add information about the fund board's role to the tailored mutual and exchange-traded ...